# One Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/one-biosciences

- Industry: Healthcare Specialists
- Headquarters: Paris, France
- Website: www.onebiosciences.fr
- Total disclosed funding: $18M
- Latest round: Series A (Jul 17, 2025)
- Investors on record: 8

## About

Based in France, One Biosciences SAS specializes in advanced diagnostic solutions utilizing AI-powered single-cell technologies to enhance cancer treatment outcomes.One Biosciences SAS, founded in 2020, is a Paris-based company that develops innovative diagnostic solutions for cancer treatment. The company has raised EUR 15.000 mn in its latest funding round, the Series A, on July 17, 2025, co-led by Redmile Group and Blast.Club, along with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures. The firm has completed one deal to date.One Biosciences specializes in advanced diagnostic solutions that leverage AI-powered single-cell technologies to address tumor heterogeneity in cancer treatment. The company’s flagship products, OneMap™ and OneCure™, serve as breakthrough platforms that provide actionable insights from routine tumor biopsy specimens. OneMap™ enables clinicians to make data-driven therapeutic decisions by delivering comprehensive single-cell reports within a rapid two-week turnaround time. OneCure™ focuses on optimizing patient selection and identifying predictive biomarkers for clinical trials in partnership with pharmaceutical and biotech companies. The company primarily serves healthcare institutions, pharmaceutical firms, and research organizations across North America and Europe, with a commitment to transforming precision medicine in oncology.One Biosciences generates revenue through strategic partnerships and collaborations with pharmaceutical and biotech companies, focusing on B2B transactions. The company’s revenue model is anchored in the provision of services related to its proprietary diagnostic platforms, where clients pay for access to single-cell analysis and reporting. These transactions are structured around project-based fees or subscription models for ongoing access to the company's insights and technology. The offerings, particularly OneMap™ and OneCure™, are designed to meet the needs of its client base, which includes clinical practitioners and researchers seeking to enhance the efficacy of cancer treatments. The pricing structure reflects the value of rapid, high-quality insights that facilitate clinical decision-making and optimize clinical trial outcomes.In July 2025, One Biosciences SAS raised EUR 15.000 mn in Series A funding to accelerate its flagship OneMap™ platform and support the scaling of strategic partnerships. The company plans to expand into new markets, specifically targeting North America and Europe, to enhance its presence in the oncology diagnostics space.

## Funding rounds

- Series A, Jul 17, 2025, $18M — Sofinnova Partners, Invus [DUP], Kima Ventures, Redmile Group, Galion.exe, Polytechnique Ventures, Blast.Club, Adamed Technology

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A
- Invus [DUP] — Series A
- Kima Ventures (https://capitalatlas.ai/funds/kima-ventures) — Series A
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series A
- Galion.exe (https://capitalatlas.ai/funds/galion-exe) — Series A
- Polytechnique Ventures (https://capitalatlas.ai/funds/polytechnique-ventures) — Series A
- Blast.Club (https://capitalatlas.ai/funds/blast-club) — Series A
- Adamed Technology (https://capitalatlas.ai/funds/adamed-technology) — Series A